| Name | Title | Contact Details |
|---|
Smith-Sterling Dental Laboratories is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.
Lycera is a biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer. Our approach builds on an in-depth understanding of the orchestration of immune response in disease progression. When working correctly, the immune system can respond aggressively and with precise targeting to eliminate infectious pathogens or cancer cells. Incorrect regulation can cause the immune system to attack healthy tissue as foreign, supporting onset and progression of autoimmune disease while disruption of anti-tumor immune responses can shield cancer cells from the immune system and allow them to proliferate. Lycera is rapidly building a portfolio of selective immune modulators with mechanisms we believe will translate into improved outcomes for patients. With senior leadership and a team of scientists who represent the best of their fields, Lycera has the expertise and insight necessary to develop innovative therapies able to restore immune balance and significantly improve treatment for patients affected by these diseases around the world. Lycera product development programs are enhanced by our established global relationships with many leading chemists, scientists and clinical researchers. We are currently advancing novel small molecule compounds from distinct, yet complementary, areas of research, including immune metabolism, cell signaling and immune cell differentiation.
Targacept`s clinical pipeline is built on a unique class of therapeutic targets.